Abstract
Metabolomics holds promise as a non-invasive tool for revealing biochemical pathways implicated in multiple sclerosis (MS) (1). Specifically, Ingenuity Pathway Analysis (IPA) can be used to identify pathways associated with proteins and metabolites of relevance in MS as biomarkers or targets of intervention (2).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
